Segment Data (Tables)

9 Months Ended

Sep. 30, 2022

Schedule of Segment Reporting Information by Reportable Segment

Selected information by reportable segment was as follows:



	Successor		Predecessor
	Three Months Ended September 30, 2022		Three Months Ended September 24, 2021
Net sales:
Specialty Brands	$	303.5	$	359.7
Specialty Generics	161.9		147.5
Net sales	$	465.4	507.2
Operating income (loss):
Specialty Brands	$	43.7	$	189.9
Specialty Generics (1)	(9.0)		15.2
Segment operating income	34.7		205.1
Unallocated amounts:
Corporate and unallocated expenses (2)	(15.0)		(20.8)
Depreciation and amortization	(148.5)		(168.4)
Share-based compensation	(0.5)		(2.4)
Restructuring charges, net	(2.2)		(11.0)
Non-restructuring impairment charges	—		—
Separation costs (3)	(6.9)		(0.1)
Opioid-related litigation settlement loss	—		(125.0)
Bad debt expense - customer bankruptcy	(5.8)		—
Operating loss	$	(144.2)	$	(122.6)

(1)Includes $17.9 million of fresh-start inventory-related expense during the three months ended September 30, 2022 (Successor) primarily driven by the Company's change in accounting estimate as disclosed in Note 1.

(2)Includes administration expenses and certain compensation, legal, environmental and other costs not charged to the Company's reportable segments.

(3)Represents costs included in selling, general and administrative expenses, primarily related to expenses incurred related to the severance of certain former executives of the Predecessor, in addition to professional fees and costs incurred as the Company explores potential sales of non-core assets to enable further deleveraging post-emergence.


	Successor		Predecessor
	Period from June 17, 2022 through September 30, 2022		Period from January 1, 2022 through June 16, 2022		Nine Months Ended September 24, 2021
Net sales:
Specialty Brands	$	361.7	$	587.1	$	1,149.6
Specialty Generics	188.7		287.5		462
Net sales	$	550.4	$	874.6	$	1,611.6
Operating income (loss):
Specialty Brands	$	48.2	$	267.2	$	588.6
Specialty Generics (1)	(8.7)		65.3		73.8
Segment operating income	39.5		332.5		662.4
Unallocated amounts:
Corporate and unallocated expenses (2)	(15.9)		(48.2)		(69.1)
Depreciation and amortization	(196.9)		(321.8)		(506.1)
Share-based compensation	(0.5)		(1.7)		(8.4)
Restructuring charges, net	(3.3)		(9.6)		(17.5)
Non-restructuring impairment charges	—		—		(64.5)
Separation costs (3)	(16.1)		(9.0)		(1.0)
Opioid-related litigation settlement loss	—		—		(125.0)
Bad debt expense - customer bankruptcy	(5.8)		—		—
Operating loss	$	(199.0)	$	(57.8)	$	(129.2)

(1)Includes $20.3 million of fresh-start inventory-related expense during the period from June 17, 2022 through September 30, 2022 (Successor) primarily driven by the Company's change in accounting estimate as disclosed in Note 1.

(2)Includes administration expenses and certain compensation, legal, environmental and other costs not charged to the Company's reportable segments.

(3)Represents costs included in selling, general and administrative expenses, primarily related to expenses incurred related to the Predecessor directors' and officers' insurance policies and severance for the former CEO and certain former executives of the Predecessor, in addition to professional fees and costs incurred as the Company explores potential sales of non-core assets to enable further deleveraging post-emergence.

Schedule of Net Sales from External Customers by Products

Net sales by product family within the Company's reportable segments were as follows:



	Successor		Predecessor
	Three Months Ended September 30, 2022		Three Months Ended September 24, 2021
Acthar Gel	$	125.7	$	143.4
INOmax	80.7		98.4
Ofirmev	—		4.7
Therakos	58.0		62.5
Amitiza (1)	37.1		49.6
Other	2.0		1.1
Specialty Brands	303.5		359.7

Opioids	46.5		46.5
ADHD	11.6		8.7
Addiction treatment	16.6		15.3
Other	2.9		2.9
Generics	77.6		73.4
Controlled substances	19.7		19.4
APAP	57.9		49.6
Other	6.7		5.1
API	84.3		74.1
Specialty Generics	161.9		147.5
Net sales	$	465.4	$	507.2

(1)Amitiza consists of both product net sales and royalties. Refer to Note 4 for further details on Amitiza's revenues.


	Successor		Predecessor
	Period from June 17, 2022 through September 30, 2022		Period from January 1, 2022 through June 16, 2022		Nine Months Ended September 24, 2021
Acthar Gel	$	153.2	$	221.9	$	423.9
INOmax	94.2		165.8		338.3
Ofirmev	(0.2)		2.5		24.0
Therakos	68.2		109.6		197.8
Amitiza (1)	42.9		81.5		155.8
Other	3.4		5.8		9.8
Specialty Brands	361.7		587.1		1,149.6

Opioids	55.2		88.8		155.0
ADHD	13.4		17.5		24.8
Addiction treatment	19.1		30.0		47.7
Other	3.0		4.9		8.4
Generics	90.7		141.2		235.9
Controlled substances	21.4		37.6		62.4
APAP	69.2		96.5		146.8
Other	7.4		12.2		16.9
API	98.0		146.3		226.1
Specialty Generics	188.7		287.5		462.0
Net sales	$	550.4	$	874.6	$	1,611.6

(1)Amitiza consists of both product net sales and royalties. Refer to Note 4 for further details on Amitiza's revenues.